Philips Spotlights New Cardiology Solutions and Unveils Ultrasound Technology at European Society of Cardiology Congress 2014

— Innovative cardiology solutions help deliver better care for more patients, respond to biggest challenges facing cardiologists

ANDOVER, Mass., Aug. 29, 2014 /PRNewswire/ – Royal Philips (NYSE: PHG AEX: PHIA) today announced its presence at the European Society of Cardiology (ESC) Congress 2014, where the company …

Read More

Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS

— No overall statistically significant increased risk of bladder cancer in patients ever exposed to pioglitazone in a completed 10-year epidemiological study

OSAKA, Japan, Aug. 29, 2014 /PRNewswire/ — Takeda Pharmaceutical Company Limited ("Takeda") today announced the completion of the post-marketing commitment and submissions of …

Read More

Frost & Sullivan Applauds Volpara Solutions’ Clear Vision in Identifying the Importance of Dose Tracking and Quantitative Analytics in the Early Detection of Breast Cancer

Volpara Solutions is the only company with a dose measurement tool specifically for breast imaging

MOUNTAIN VIEW, Calif., Aug. 26, 2014 /PRNewswire/ — Based on its recent analysis of the breast imaging solutions market, Frost & Sullivan recognizes Volpara Solutions with the 2014 North American …

Read More

ViiV Healthcare receives FDA approval for Triumeq® (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection

LONDON, Aug. 23, 2014 /PRNewswire/ — ViiV Healthcare announced today that the US Food and Drug Administration (FDA) has approved Triumeq® (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the treatment of HIV-1 infection.1 Triumeq is ViiV Healthcare’s first dolutegravir-based fixed-dose …

Read More

Coherus Announces CHS-1420 (Investigational Adalimumab Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study

— Company To Pursue Next Stage of Development

REDWOOD CITY, California, Aug. 15, 2014  /PRNewswire/ — Coherus BioSciences, Inc. ("Coherus") today announced that CHS-1420, its proposed biosimilar of adalimumab (Humira®), met the primary endpoint in a pivotal clinical pharmacokinetic (PK) similarity study that compared …

Read More